ABEONA THERAPEUTICS INC.ABEO
| Dec 31,
2011 | Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 |
|---|
| Cash and cash equivalents | 2 | 396,000 | 424,000 | 12 | 40 | 69 | 138 | 19 | 129 | 13 | 33 | 14 |
|---|
| Short-term investments | - | - | - | - | - | - | - | 66 | - | 82 | 12 | 38 |
|---|
| Restricted cash | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Accounts receivable | - | - | - | - | - | - | - | - | - | - | 3 | - |
|---|
| Other receivables | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Prepaid expenses and other current assets | 39,000 | 251,000 | 77,000 | - | 315,000 | 155,000 | 3 | 4 | 3 | 3 | 7 | 0 |
|---|
| Total current assets | 3 | 2 | 575,000 | 12 | 41 | 69 | 141 | 89 | 132 | 98 | 55 | 53 |
|---|
| Property and equipment, net | 51,000 | 7,000 | 6,000 | 4,000 | 350,000 | 721,000 | 1 | 9 | 13 | 11 | 12 | 6 |
|---|
| Right-of-use lease assets | - | - | - | - | - | - | - | - | 8 | 7 | 9 | 5 |
|---|
| Licensed technology, net | 362,000 | - | - | 5 | 7 | 8 | 4 | 43 | 36 | 2 | 1 | - |
|---|
| Other assets | 59,000 | 42,000 | 32,000 | 32,000 | 62,000 | 66,000 | - | - | - | - | - | 0 |
|---|
| Total assets | 4 | 2 | 613,000 | 17 | 80 | 111 | 179 | 174 | 223 | 151 | 80 | 64 |
|---|
| Accounts payable | 2 | 2 | 863,000 | 2 | 875,000 | 4 | 2 | 6 | 4 | 5 | 4 | 2 |
|---|
| Accrued expenses | 857,000 | 857,000 | 857,000 | - | - | - | - | 4 | 6 | 3 | 6 | 4 |
|---|
| Current portion of lease liability | - | - | - | - | - | - | - | - | 2 | 2 | 2 | 2 |
|---|
| Current portion of payable to licensor | - | - | - | - | - | - | - | - | 27 | 32 | 5 | - |
|---|
| Other current liabilities | - | - | - | - | - | - | - | - | - | - | - | 0 |
|---|
| Total current liabilities | 12 | 7 | 9 | 3 | 1 | 8 | 6 | 20 | 39 | 42 | 17 | 8 |
|---|
| Payable to licensor | - | - | - | - | - | - | - | - | - | - | 4 | 4 |
|---|
| Long-term lease liabilities | - | - | - | - | - | - | - | - | 6 | 5 | 8 | 6 |
|---|
| Warrant liabilities | - | - | - | - | - | - | - | - | - | - | - | 20 |
|---|
| Other long-term liabilities | - | - | - | - | - | - | - | - | - | - | 200,000 | - |
|---|
| Total liabilities | 21 | 19 | 15 | 12 | 12 | 12 | 9 | 40 | 45 | 49 | 28 | 37 |
|---|
| Preferred stock - $0.01 par value; authorized 2,000,000 shares; No shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively | - | - | - | - | - | - | - | - | - | - | - | - |
|---|
| Common stock - $0.01 par value; authorized 200,000,000 shares; 17,719,720 and 5,888,217 shares issued and outstanding as of December 31, 2022 and December 31, 2021, respectively | 239,000 | 247,000 | 257,000 | 200,000 | 328,000 | 403,000 | 469,000 | 479,000 | 836,000 | 961,000 | 1 | 0 |
|---|
| Additional paid-in capital | 238 | 251 | 251 | 301 | 378 | - | - | - | - | - | - | 722 |
|---|
| Accumulated deficit | -255,441,000 | -267,972,000 | -266,421,000 | -296,074,000 | -310,600,000 | -332,473,000 | -359,792,000 | -410,188,000 | -486,470,000 | -570,704,000 | -655,640,000 | -695 |
|---|
| Accumulated other comprehensive loss | - | - | - | - | - | - | - | - | - | -10,000 | -27,000 | -0 |
|---|
| Total stockholders’ equity | -17,606,000 | -17,076,000 | -14,779,000 | 5 | 68 | 99 | 170 | 134 | 178 | 103 | 51 | 27 |
|---|
| Total liabilities and stockholders’ equity | 4 | 2 | 613,000 | 17 | 80 | 111 | 179 | 174 | 223 | 151 | 80 | 64 |
|---|